Is LRLCY.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

128 people get LRLCY.PK articles and Market Currents by email alert.

Get email alerts on LRLCY.PK »

HEADLINES:

Procter & Gamble, Colgate-Palmolive, Reckitt Benckiser, L'Oreal: Which Stock Is The Best Bet For Now?
Timing Best Buy • Wed, Feb 20 • 1 Comment
L'Oreal SA Management Discusses 2012 Results - Earnings Call Transcript
Tue, Feb 12
6 Consumer-Products Multinationals With High Emerging Market Sales
David Hunkar • Thu, Jan 31 • 1 Comment
Comparing Dividend Payout Ratios Across Regions
David Hunkar • Wed, Dec 26, 2012 • 1 Comment
How To Play The Cosmeceutical Market
Charles Moscoe • Tue, Dec 25, 2012 • 3 Comments
Voce Capital Management Engages Proxy Fight Against Obagi Board
Scott Matusow • Thu, Dec 6, 2012 • 7 Comments
Cosmeceuticals: Bridging The Gap Between Cosmetics And Pharmaceuticals
Charles Moscoe • Thu, Nov 22, 2012 • 5 Comments
A Message To VOCE Capital And Obagi Shareholders: Take Action Or Get Off The Pot
Scott Matusow • Fri, Oct 19, 2012 • 17 Comments
Buy Stocks Shifting Their Focus Toward Women
Jae Jun • Wed, Oct 10, 2012 • 1 Comment
L'Oreal SA Management Discusses Q2 2012 (H1 2012) Results - Earnings Call Transcript
Wed, Aug 29, 2012
Investing For Growth In An Age Of Deleveraging
Stock Whiz • Mon, Aug 20, 2012 • 1 Comment
Obagi Will Still See An Acquisition Soon: Here's Why
Scott Matusow • Tue, Aug 7, 2012 • 17 Comments
Obagi Files 8k Officially Removing Poison Pill, Clears Way For Acquisition
Scott Matusow • Wed, Jul 11, 2012 • 31 Comments
European Dividend Aristocrats: The Comprehensive List
Ploutos • Fri, Jun 29, 2012 • 28 Comments
L'Oreal Reaches $24 By Selling More Online
Trefis • Wed, Jun 27, 2012 • 1 Comment
Top 10 Mega Caps To Own Right Now, Get Ready For A Surprise
Retracement • Wed, Jun 13, 2012 • 5 Comments
Obagi Medical Products Shareholders Vote Down Management's Poison Pill
Scott Matusow • Thu, Jun 7, 2012 • 3 Comments
Avon's New CEO To Cleanse Brand Image As L'Oreal Sparks Upgrade Rumors
Benzinga • Wed, Apr 11, 2012
L'oreal's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 15, 2012
7 Wide Moat, Non-U.S. Companies That Value Investors Should Watch
Uncle Scrooge • Wed, Jan 11, 2012 • 9 Comments

To learn more about Seeking Alpha Pro, click here.

L'Oreal Reaches $24 By Selling More Online
Trefis • Wed, Jun 27, 2012 • 1 Comment
L'Oreal Returns to Market Share Gains
Véronique Adam • Wed, Jul 14, 2010
L'Oreal: Fully Priced but Sales Indicate Return to Market Share Gain
Véronique Adam • Fri, Apr 23, 2010
L’Oreal Looks Fully Priced
Véronique Adam • Wed, Sep 2, 2009
Little Potential in L'Oreal
Véronique Adam • Sun, Aug 2, 2009

Procter & Gamble, Colgate-Palmolive, Reckitt Benckiser, L'Oreal: Which Stock Is The Best Bet For Now?
Timing Best Buy • Wed, Feb 20 • 1 Comment
6 Consumer-Products Multinationals With High Emerging Market Sales
David Hunkar • Thu, Jan 31 • 1 Comment
Comparing Dividend Payout Ratios Across Regions
David Hunkar • Wed, Dec 26, 2012 • 1 Comment
How To Play The Cosmeceutical Market
Charles Moscoe • Tue, Dec 25, 2012 • 3 Comments
Voce Capital Management Engages Proxy Fight Against Obagi Board
Scott Matusow • Thu, Dec 6, 2012 • 7 Comments
Cosmeceuticals: Bridging The Gap Between Cosmetics And Pharmaceuticals
Charles Moscoe • Thu, Nov 22, 2012 • 5 Comments
A Message To VOCE Capital And Obagi Shareholders: Take Action Or Get Off The Pot
Scott Matusow • Fri, Oct 19, 2012 • 17 Comments
Buy Stocks Shifting Their Focus Toward Women
Jae Jun • Wed, Oct 10, 2012 • 1 Comment
Investing For Growth In An Age Of Deleveraging
Stock Whiz • Mon, Aug 20, 2012 • 1 Comment
Obagi Will Still See An Acquisition Soon: Here's Why
Scott Matusow • Tue, Aug 7, 2012 • 17 Comments
Obagi Files 8k Officially Removing Poison Pill, Clears Way For Acquisition
Scott Matusow • Wed, Jul 11, 2012 • 31 Comments
European Dividend Aristocrats: The Comprehensive List
Ploutos • Fri, Jun 29, 2012 • 28 Comments
Top 10 Mega Caps To Own Right Now, Get Ready For A Surprise
Retracement • Wed, Jun 13, 2012 • 5 Comments
Obagi Medical Products Shareholders Vote Down Management's Poison Pill
Scott Matusow • Thu, Jun 7, 2012 • 3 Comments
Avon's New CEO To Cleanse Brand Image As L'Oreal Sparks Upgrade Rumors
Benzinga • Wed, Apr 11, 2012
7 Wide Moat, Non-U.S. Companies That Value Investors Should Watch
Uncle Scrooge • Wed, Jan 11, 2012 • 9 Comments
Going Global and Finding Value With Avon Products
Jim Pyke • Sat, Mar 5, 2011 • 3 Comments
Avon Products Reports Earnings, But Where’s the Buy-Out?
Investment Underground • Fri, Oct 29, 2010 • 2 Comments
Morning Report: Futures Fall With Mixed Foreign Trade
optionMONSTER • Tue, Oct 12, 2010
Nestle: Superior Pricing Power Plus Earnings Quality Combine for a Tasty Outlook
Véronique Adam • Wed, Sep 1, 2010 • 1 Comment

L'Oreal SA Management Discusses 2012 Results - Earnings Call Transcript
Tue, Feb 12
L'Oreal SA Management Discusses Q2 2012 (H1 2012) Results - Earnings Call Transcript
Wed, Aug 29, 2012
L'oreal's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 15, 2012
L'Oreal SA's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Sun, Oct 16, 2011

There are no News articles on LRLCY.PK.

LRLCY.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for LRLCY.PK.

Sector: Healthcare

Industry: Drug Related Products

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, April 25, 1:56 PM The Avon Lady might be rolling around in her grave with news of the latest development in the world of fast-pace cosmetics selling. Chanel is introducing new vending machines which will dispense high-end cosmetic on demand. For a large part of the luxury cosmetics industry the focus has been on trying convince Chinese consumers to buy fragrances and make-up, but now more firms like Chanel are starting to dip into new channels. Cosmetics sellers: Avon Products (AVP), Estee Lauder (EL), Ulta Salon (ULTA), L'Oreal (LRLCY.PK), Sephora (LVMHF.PK). Comment! [Consumer, Global & FX]
Friday, March 22, 7:27 AM L'Oreal (LRLCY.PK) launches a variety of new products in China with an aim of chopping into Procter & Gamble's (PG) market share for beauty and personal care products. The French company is taking a customized approach to its brands in the nation as it tries to catch up to P&G which ran off with an early in China - but has grown a bit complacent with innovation. Comment! [Consumer, Global & FX]
Friday, September 14, 2012, 11:11 AM L'Oreal's (LRLCY.PK -0.5%) Lancome USA unit has received an FDA warning about the marketing of some of its anti-wrinkle products, saying the products are making claims suggesting they are drugs. Several skin care and eye rejuvenator products claim to "boost the activity of genes and stimulate the production of youth proteins" or provide "immediate lifting" to the eye area, which violate federal drug laws. Comment! [Healthcare, Global & FX]
Tuesday, August 7, 2012, 9:33 AM Avon (AVP) has held serious talks about acquiring Obagi Medical Products (OMPI), although it hasn't yet bid high enough, writes SA author Scott Matusow, while L'Oreal (LRLCY.PK) is also showing interest. Matusow reckons that with institutions owning about 90% of the company, and with "the majority of them" wanting Obagi sold," a deal will happen soon. Comment! [Healthcare, On the Move]
Tuesday, July 12, 2011, 12:07 PM eBay (EBAY -0.6%) faces a ruling in a case filed by L'Oreal (LRLCY.PK) finding online marketplaces are liable over items sold on their websites. A European court says national courts can order website operators to take measures to stop existing infringements of intellectual property rights by online users. Comment! [Tech, Global & FX]
Tuesday, October 12, 2010, 8:15 AM L'Oreal (LRLCY.PK) is set to make a bid for Avon Products (AVP), at least according to a report in the U.K.'s Daily Mail which suggests the cash offer will likely top $44/share. The speculation has pushed Avon shares +9.2% premarket to $36.20. Comment!
Wednesday, August 25, 2010, 11:50 AM Despite calls for Genzyme (GENZ) not to take less than $75-80 a share, Sanofi-Aventis (SNY) isn't likely to go over a currently authorized $70 and may look elsewhere, sources tell Bloomberg. And key Sanofi shareholders Total (TOT) and L'Oreal (LRLCY.PK) don't want a raised bid. Comment!

LRLCY.PK L'oreal Co Adr

LRLCY.PK

L'oreal Co Adr